FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown
On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1 For Novo Nordisk, the milestone is more than a product expansion. It’s a high‑stakes move to defend its GLP‑1 franchise, widen access beyond injections, and reassert momentum after a volatile year in which investors questioned its growth trajectory and competitive positioning. Reuters+1 What the FDA approved on December 22, 2025 The Wegovy